IDOV-2
AssetAlso IDOV-Immune
Intravenously deliverable oncolytic virus for cancer immunotherapy.
- Stage
- Phase 1
- Modality
- Other
- Target
- Not known
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Advanced solid tumor
Phase 1, globenewswire.com, 1 Oct 2026
Solid tumor
Phase 1, globenewswire.com, 1 Oct 2026
In the full profile
- Owner and partners1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.